{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T06:59:09Z","timestamp":1782197949883,"version":"3.54.5"},"reference-count":42,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.vaccine.2018.11.077","type":"journal-article","created":{"date-parts":[[2019,1,16]],"date-time":"2019-01-16T09:16:55Z","timestamp":1547630215000},"page":"1229-1234","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Safety of 9-valent human papillomavirus vaccine administration among pregnant women: Adverse event reports in the Vaccine Adverse Event Reporting System (VAERS), 2014\u20132017"],"prefix":"10.1016","volume":"37","author":[{"given":"Claudia S.","family":"Landazabal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro L.","family":"Moro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paige","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad B.","family":"Omer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.vaccine.2018.11.077_b0005","first-page":"300","article-title":"Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the Advisory Committee on Immunization Practices","volume":"64","author":"Petrosky","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2018.11.077_b0010","series-title":"December 10, 2014 Approval letter\u2014GARDASIL 9","author":"Gruber","year":"2014"},{"key":"10.1016\/j.vaccine.2018.11.077_b0015","unstructured":"Centers for Disease Control and Prevention. HPV Vaccine Information for Clinicians. U.S. Department of Health and Human Services. <https:\/\/www.cdc.gov\/hpv\/hcp\/need-to-know.pdf>. Published December 20, 2016. [Accessed January 2018]."},{"issue":"49","key":"10.1016\/j.vaccine.2018.11.077_b0020","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.15585\/mmwr.mm6549a5","article-title":"Use of a 2-dose schedule for human papillomavirus vaccination - updated recommendations of the Advisory Committee on Immunization Practices","volume":"65","author":"Meites","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2018.11.077_b0025","unstructured":"Merck Sharp & Dohme Corp. Highlights of Prescribing Information. Gardasil\u00ae9 (Human Papillomavirus 9-valent Vaccine, Recombinant). Merck & Co., Inc. <https:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM426457.pdf>. Published 2014. Updated February 2018 [accessed April 2018]."},{"key":"10.1016\/j.vaccine.2018.11.077_b0030","unstructured":"Merck Sharp & Dohme Corp. Highlights of Prescribing Information. GARDASIL\u00ae [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant]. Merck & Co., Inc. <https:\/\/www.fda.gov\/downloads\/biologicsbloodvaccines\/vaccines\/approvedproducts\/ucm111263.pdf>. Published 2006. Updated April 2015 [accessed 2018]."},{"issue":"Rr-05","key":"10.1016\/j.vaccine.2018.11.077_b0035","first-page":"1","article-title":"Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"63","author":"Markowitz","year":"2014","journal-title":"MMWR Recomm Rep: Morb Mortal Wkl Rep Recomm Rep"},{"issue":"Rr-2","key":"10.1016\/j.vaccine.2018.11.077_b0040","first-page":"1","article-title":"Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"56","author":"Markowitz","year":"2007","journal-title":"MMWR Recomm Rep: Morb Mortal Wkl Rep Recomm Rep"},{"issue":"4","key":"10.1016\/j.vaccine.2018.11.077_b0045","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.vaccine.2014.11.047","article-title":"Safety of quadrivalent human papillomavirus vaccine (Gardasil) in pregnancy: adverse events among non-manufacturer reports in the Vaccine Adverse Event Reporting System, 2006\u20132013","volume":"33","author":"Moro","year":"2015","journal-title":"Vaccine"},{"issue":"29","key":"10.1016\/j.vaccine.2018.11.077_b0050","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.1016\/j.vaccine.2015.04.014","article-title":"Final report on exposure during pregnancy from a pregnancy registry for quadrivalent human papillomavirus vaccine","volume":"33","author":"Goss","year":"2015","journal-title":"Vaccine"},{"issue":"13","key":"10.1016\/j.vaccine.2018.11.077_b0055","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1056\/NEJMoa1612296","article-title":"Quadrivalent HPV vaccination and the risk of adverse pregnancy outcomes","volume":"376","author":"Scheller","year":"2017","journal-title":"New England J Med"},{"issue":"3","key":"10.1016\/j.vaccine.2018.11.077_b0060","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/AOG.0000000000002191","article-title":"Maternal and infant outcomes after human papillomavirus vaccination in the periconceptional period or during pregnancy","volume":"130","author":"Lipkind","year":"2017","journal-title":"Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.vaccine.2018.11.077_b0065","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/AOG.0000000000002694","article-title":"Risk of spontaneous abortion after inadvertent human papillomavirus vaccination in pregnancy","volume":"132","author":"Kharbanda","year":"2018","journal-title":"Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.vaccine.2018.11.077_b0070","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2015-4387","article-title":"Safety profile of the 9-valent HPV vaccine: a combined analysis of 7 phase III clinical trials","volume":"138","author":"Moreira","year":"2016","journal-title":"Pediatrics"},{"issue":"4","key":"10.1016\/j.vaccine.2018.11.077_b0075","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/00006454-200404000-00002","article-title":"Understanding vaccine safety information from the Vaccine Adverse Event Reporting System","volume":"23","author":"Varricchio","year":"2004","journal-title":"Pediatr Infect Dis J"},{"issue":"5","key":"10.1016\/j.vaccine.2018.11.077_b0080","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/pds.616","article-title":"Safety considerations for new vaccine development","volume":"10","author":"Ellenberg","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2018.11.077_b0085","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/S0264-410X(01)00291-2","article-title":"Detection of adverse events: what are the current sensitivity limits during clinical development?","volume":"20","author":"Fritzell","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.11.077_b0090","unstructured":"U.S. Food and Drug Administration. U.S. Code of Federal Regulations, 21 CFR 600.80. Silver Spring, MD: U.S. Department of Health and Human Services. <https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/CFRSearch.cfm?fr=600.80>. Updated August 14, 2017 [accessed April 2018]."},{"key":"10.1016\/j.vaccine.2018.11.077_b0095","unstructured":"Institute of Medicine (US) Committee on Review of Priorities in the National Vaccine Plan. Priorities for the National Vaccine Plan. Washington (DC): National Academies Press (US); 2010."},{"key":"10.1016\/j.vaccine.2018.11.077_b0100","unstructured":"Health Resources and Services Administration. Vaccine Injury Table. U.S. Department of Health and Human Services. <https:\/\/www.hrsa.gov\/sites\/default\/files\/vaccinecompensation\/vaccineinjurytable.pdf>. [accessed October 2018]."},{"key":"10.1016\/j.vaccine.2018.11.077_b0105","unstructured":"Centers for Disease Control and Prevention. Understanding the Vaccine Adverse Event Reporting System (VAERS). U.S. Department of Health and Human Services. <https:\/\/www.cdc.gov\/vaccines\/hcp\/patient-ed\/conversations\/downloads\/vacsafe-vaers-color-office.pdf>. Updated February 2013 [accessed March 2018]."},{"issue":"28","key":"10.1016\/j.vaccine.2018.11.077_b0110","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1016\/j.vaccine.2015.05.006","article-title":"Vaccination errors reported to the Vaccine Adverse Event Reporting System, (VAERS) United States, 2000\u20132013","volume":"33","author":"Hibbs","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.11.077_b0115","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. MedDRA. <http:\/\/www.ich.org\/products\/meddra.html>. [accessed April 2018]."},{"key":"10.1016\/j.vaccine.2018.11.077_b0120","unstructured":"Chapter 1 - Overview of Obstetrics. In: Cunningham F, Leveno K, Bloom S, et al., editors. Williams Obstetrics, 23 ed. New York, NY: McGraw-Hill Companies, Inc.; 2010."},{"key":"10.1016\/j.vaccine.2018.11.077_b0125","unstructured":"Chapter 9 - Abortion. In: Cunningham F, Leveno K, Bloom S, et al., editors. Williams Obstetrics, 23 ed. New York, NY: McGraw-Hill Companies, Inc.; 2010."},{"key":"10.1016\/j.vaccine.2018.11.077_b0130","unstructured":"Medical College of Wisconsin. Pregnancy Date Calculator. <https:\/\/www.mcw.edu\/calculators\/pregnancydate.htm>. [accessed January 2018]."},{"key":"10.1016\/j.vaccine.2018.11.077_b0135","unstructured":"Chapter 8 - Prenatal Care. In: Cunningham F, Leveno K, Bloom S, et al., editors. Williams Obstetrics, 23 ed. New York, NY: McGraw-Hill Companies, Inc.; 2010."},{"issue":"6","key":"10.1016\/j.vaccine.2018.11.077_b0140","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"9","key":"10.1016\/j.vaccine.2018.11.077_b0145","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/pds.1107","article-title":"Comparing data mining methods on the VAERS database","volume":"14","author":"Banks","year":"2005","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2018.11.077_b0150","unstructured":"Office for Human Research Protections (OHRP). U.S. Code of Federal Regulations, 45 CFR 46.102. U.S. Department of Health and Human Services. <https:\/\/www.hhs.gov\/ohrp\/regulations-and-policy\/regulations\/45-cfr-46\/index.html#46.102>. Updated January 15, 2010 [accessed April 2018]."},{"issue":"6","key":"10.1016\/j.vaccine.2018.11.077_b0155","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1592\/phco.24.8.743.36068","article-title":"Replication of the Weber effect using postmarketing adverse event reports voluntarily submitted to the United States Food and Drug Administration","volume":"24","author":"Hartnell","year":"2004","journal-title":"Pharmacotherapy"},{"issue":"5","key":"10.1016\/j.vaccine.2018.11.077_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2011.06.047","article-title":"Adverse events following administration to pregnant women of influenza A (H1N1) 2009 monovalent vaccine reported to the Vaccine Adverse Event Reporting System","volume":"205","author":"Moro","year":"2011","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.vaccine.2018.11.077_b0165","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/00001648-199101000-00006","article-title":"The fetal life table revisited: spontaneous abortion rates in three Kaiser Permanente cohorts","volume":"2","author":"Goldhaber","year":"1991","journal-title":"Epidemiology (Cambridge, Mass)"},{"issue":"4","key":"10.1016\/j.vaccine.2018.11.077_b0170","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1093\/oxfordjournals.aje.a113220","article-title":"Spontaneous abortion over time: comparing occurrence in two cohorts of women a generation apart","volume":"114","author":"Wilcox","year":"1981","journal-title":"Am J Epidemiol"},{"issue":"1","key":"10.1016\/j.vaccine.2018.11.077_b0175","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1365-3016.1994.tb00436.x","article-title":"Vaginal bleeding and adverse reproductive outcomes: a meta-analysis","volume":"8","author":"Ananth","year":"1994","journal-title":"Paediatr Perinat Epidemiol"},{"key":"10.1016\/j.vaccine.2018.11.077_b0180","doi-asserted-by":"crossref","unstructured":"Arana J. Adverse events following 9-valent human papillomavirus vaccine (9vHPV) reported to the Vaccine Adverse Event Reporting System (VAERS). Presented at the Meeting of the Advisory Committee on Immunization Practices (ACIP), Atlanta, GA, February 21-22, 2018.","DOI":"10.1093\/ofid\/ofy210.2116"},{"issue":"3","key":"10.1016\/j.vaccine.2018.11.077_b0185","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.jadohealth.2012.07.003","article-title":"Clinical trial experience with prophylactic human papillomavirus 6\/11\/16\/18 vaccine in young black women","volume":"52","author":"Clark","year":"2013","journal-title":"J Adolescent Health: Off Publ Soc Adolescent Med"},{"issue":"22","key":"10.1016\/j.vaccine.2018.11.077_b0190","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1016\/S0264-410X(99)00132-2","article-title":"An overview of the vaccine adverse event reporting system (VAERS) as a surveillance system. VAERS Working Group","volume":"17","author":"Singleton","year":"1999","journal-title":"Vaccine"},{"issue":"36","key":"10.1016\/j.vaccine.2018.11.077_b0195","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1016\/j.vaccine.2015.07.035","article-title":"Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)","volume":"33","author":"Shimabukuro","year":"2015","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2018.11.077_b0200","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1016\/j.vaccine.2011.12.040","article-title":"In the heat of a signal: responding to a vaccine safety signal for febrile seizures after 2010\u201311 influenza vaccine in young children, United States","volume":"30","author":"Broder","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.11.077_b0205","unstructured":"Centers for Disease Control and Prevention. Human Papillomavirus (HPV) Vaccine Safety. U.S. Department of Health and Human Services. <https:\/\/www.cdc.gov\/vaccinesafety\/vaccines\/hpv-vaccine.html>. Updated January 30, 2018 [accessed March 2018]."},{"key":"10.1016\/j.vaccine.2018.11.077_b0210","unstructured":"Markowitz L. Update: Recommendations for HPV Vaccination. Centers for Disease Control and Prevention. <https:\/\/www.cdc.gov\/vaccines\/ed\/ciinc\/downloads\/2016-10-26\/recommendations-hpv-2-doses-2016.pdf>. [accessed April 2018]."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18316414?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18316414?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,8]],"date-time":"2019-10-08T18:04:22Z","timestamp":1570557862000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18316414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":42,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S0264410X18316414"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.11.077","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of 9-valent human papillomavirus vaccine administration among pregnant women: Adverse event reports in the Vaccine Adverse Event Reporting System (VAERS), 2014\u20132017","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.11.077","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}